Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem

Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem

Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026 SYDNEY, Feb. 5, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the World Health Organization (WHO) has granted the nonproprietary...

Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial

Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial

Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 Appoints US-based Chief Commercial Officer, Andrew Udell Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media....

menu
menu